Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis

Abstract

Gut dysbiosis has been associated with intestinal and extraintestinal malignancies, but whether and how carcinogenesis drives compositional shifts of the microbiome to its own benefit remains an open conundrum. Here, we show that malignant processes can cause ileal mucosa atrophy, with villous microvascular constriction associated with dominance of sympathetic over cholinergic signaling. The rapid onset of tumorigenesis induced a burst of REG3γ release by ileal cells, and transient epithelial barrier permeability that culminated in overt and long-lasting dysbiosis dominated by Gram-positive Clostridium species. Pharmacologic blockade of β-adrenergic receptors or genetic deficiency in Adrb2 gene, vancomycin, or cohousing of tumor bearers with tumor-free littermates prevented cancer-induced ileopathy, eventually slowing tumor growth kinetics. Patients with cancer harbor distinct hallmarks of this stress ileopathy dominated by Clostridium species. Hence, stress ileopathy is a corollary disease of extraintestinal malignancies requiring specific therapies. Significance: Whether gut dysbiosis promotes tumorigenesis and how it controls tumor progression remain open questions. We show that 50% of transplantable extraintestinal malignancies triggered a β-adrenergic receptor–dependent ileal mucosa atrophy, associated with increased gut permeability, sustained Clostridium spp.–related dysbiosis, and cancer growth. Vancomycin or propranolol prevented cancer-associated stress ileopathy. This article is highlighted in the In This Issue feature, p. 873

Combined Non-Invasive Prediction and New Biomarkers of Oral and Fecal Microbiota in Patients With Gastric and Colorectal Cancer

“…With the increasing research on the relationship between microbiota and systemic tumors (especially digestive tract tumors), many studies have reported that oral microbiota is related to colorectal cancer (CRC) ( Flemer et al., 2018 ; Zhang et al., 2020 ), esophageal cancer ( Chen et al., 2015 ), pancreatic cancer ( Farrell et al., 2012 ; Torres et al., 2015 ), and oral cancer ( Pushalkar et al., 2012 ; Schmidt et al., 2014 ), while fecal microbiota is related to CRC ( Flemer et al., 2017 ), liver cancer ( Ren et al., 2019 ), and breast cancer ( Terrisse et al., 2021 ). Due to microbial differences between tumor patients and healthy controls (HC), microbial detection has the potential to be a new non-invasive screen test ( Flemer et al., 2018 ; Ren et al., 2019 ; Zhang et al., 2020 ; Yonekura et al., 2021 ). In the meantime, the role of gastrointestinal (GI) microbiota in the oral cavity and stool in GC remains unknown.…”

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

“…Finally, emerging evidence indicates that carcinogenesis induces regenerating islet-derived protein 3 γ (Reg3-γ)-mediated β-adrenergic receptor-dependent epithelial permeability and, consequently, Clostridium spp.-dominant dysbiosis. This finding implicates the gut microbiota in carcinogenesis and cancer progression ( 25 ). Collectively, these data provide compelling preclinical evidence that gut microbiota mediate the efficacy of a range of anticancer therapies, including chemotherapy, radiotherapy, and immunotherapy.…”

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer

“…In our study, we used a different antibiotic cocktail including ampicillin, streptomycin, and colistin without vancomycin. We have accumulated data to show that vancomycin depletes immunosuppressive bacteria such as Clostridia spp 65 , suggesting that this point is indeed crucial. Second, Pernigoni et al 56 performed surgical castration (which is rarely used in the treatment of human PC), while we used chemical castration with an LHRH antagonist (Degarelix).…”